Stem Cell Research

 TABLE OF CONTENTS

I. SCOPE AND METHODOLOGY	1
II. REPORT SYNOPSIS	3
Foreword	3
Stem Cells	3
Exhibit 1. Stem Cells - Research Timeline	3
Market Segmentation - Stem Cells – Types, Technologies and Therapeutics Research	5
Exhibit 2.Segmentation of Global Stem Cells Market by Stem Cell Type, Technology & Therapeutic Area	5
Stem Cell Type	5
Adult Stem Cells	5
Cord Blood Stem Cells	5
Embryonic Stem Cells	6
Technology	6
Stem Cell Transplantation	6
Cell based Genomics	6
Xenotransplantation	6
Cord Blood Banking	6
Therapeutic Area	7
Neurology	7
Orthopedics	7
Oncology	7
Hematology	7
Cardiology	7
Dermatology	7
Diabetes	8
Hepatology	8
Stem Cells - Global Market Analysis	9
Exhibit 3.Stem Cells – Global Market Estimations & Predictions (2005 -2020) in US$ Million	9
Exhibit 4.List of Global Major Stem Cell Companies	10
III. MARKET DYNAMICS	12
1. Market Overview	12
Global Market Analysis	12
Analysis by Region	12
Exhibit 5. Stem Cells  – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	13
Exhibit 6. Stem Cells  – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	14
Exhibit 7. Stem Cell Research -  Global Investments (2005 -2020) in US$ Million	15
North American Stem Cells Market	16
Exhibit 8. Stem Cells – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	16
Exhibit 9. Stem Cells  – North American Market Shares (2010, 2015 & 2020) for United States and Canada	17
United States Stem Cells Market	18
US Market Scenario	18
Human Nuclear-Transfer Embryonic Stem Cells Generated	18
Setback for hESC Development	18
The Role of the NIH	18
The President's Criteria	19
NIH Cannot Fund Embryonic Stem Cell Research, Judge Rules	19
Embryonic Stem Cell Research Ban Withdrawn in the US	19
First Human Clinical Trial of Stem Cell Therapy approved by FDA	19
The US Backs Stem Cell Research	20
Exhibit 10. Stem Cell Research - United States Investments (2005 – 2020) in US$ Million	26
Exhibit 11. List of Cord Blood/ Stem Cell Banks in the United States	27
Canadian Stem Cells Market	30
Canadian Market Scenario	30
Guidelines for Stem Cell Research	30
Canadian Cord Blood Banking Sector	30
Exhibit 12. List of Cord Blood/ Stem Cell Banks in Canada	31
Exhibit 13. List of Major North American Stem Cells Companies	32
European Stem Cells Market	33
Funding for Stem Cell Research in Europe	33
Cord Blood Banking in Europe	33
Exhibit 14. Stem Cells – European Market Estimations & Predictions (2005 - 2020) for United Kingdom, Germany, France, Spain, Russia, Sweden, Switzerland and Rest of Europe in US$ Million	34
Exhibit 15. Stem Cells – European Market Shares (2010, 2015 & 2020) for United Kingdom, Germany, France, Spain, Russia, Sweden, Switzerland and Rest of Europe	35
UK Stem Cells Market	36
UK Market Scenario	36
In September 2013, disease-specific human embryonic stem lines were included in NIH registry	36
UK Cord Blood Banking Sector	37
Exhibit 16. List of Cord Blood/ Stem Cell Banks in the UK	37
German Stem Cells Market	38
German Market Scenario	38
Exhibit 17. List of Cord Blood/ Stem Cell Banks in Germany	38
French Stem Cells Market	39
French Market Scenario	39
Cord Blood Banking in France	39
Exhibit 18. List of Cord Blood/ Stem Cell Banks in France	39
Spanish Stem Cells Market	40
Spanish Market Scenario	40
Exhibit 19. List of Cord Blood/ Stem Cell Banks in Spain	40
Russian Stem Cells Market	41
Russian Market Scenario	41
Exhibit 20. List of Cord Blood/ Stem Cell Banks in Russia	41
Swedish Stem Cells Market	41
Swedish Market Scenario	41
Swiss Stem Cells Market	41
Swiss Market Scenario	41
Exhibit 21. List of Cord Blood/ Stem Cell Banks in Switzerland	42
Exhibit 22. List of Major European Stem Cells Companies	42
Market Analysis for Select Rest of Europe Countries	43
Exhibit 23. Stem Cells – Rest of Europe Market Estimations & Predictions (2005 - 2020) for Belgium, Denmark, Poland, Austria and Greece in US$ Million	43
Exhibit 24. Stem Cells – Rest of Europe Market Shares (2010, 2015 & 2020) for Belgium, Denmark, Poland, Austria and Greece	44
Exhibit 25. List of Cord Blood/ Stem Cell Banks in Rest of Europe	44
Belgium	45
Belgian Market Scenario	45
Denmark	45
Danish Market Scenario	45
Exhibit 26. Stem Cell Bank in Denmark	46
Poland	46
Polish Market Scenario	46
Exhibit 27. List of Cord Blood/ Stem Cell Banks in Poland	46
Austria	46
Austrian Market Scenario	46
Exhibit 28. List of Cord Blood/ Stem Cell Banks in Austria	46
Greece	47
Greek Market Scenario	47
Exhibit 29. List of Cord Blood/ Stem Cell Banks in Greece	47
Asia-Pacific Stem Cells Market	48
Exhibit 30. Stem Cells – Asia-Pacific Market Estimations & Predictions (2005 - 2020) for Japan, India, China, Australia, South Korea and Rest of Asia-Pacific in US$ Million	48
Exhibit 31. Stem Cells –Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, India, China, Australia, South Korea and Rest of Asia-Pacific	49
Japanese Stem Cells Market	49
Japanese Market Scenario	49
Major Advances	49
Government Policies	50
Exhibit 32. List of Cord Blood/ Stem Cell Banks in Japan	50
Indian Stem Cells Market	51
Indian Market Scenario	51
The Indian Cord Blood Banking Sector	51
Exhibit 33. List of Cord Blood/ Stem Cell Banks in India	52
Chinese Stem Cells Market	53
Chinese Market Scenario	53
Exhibit 34. List of Cord Blood/ Stem Cell Banks in China	53
Australian Stem Cells Market	54
Australian Market Scenario	54
Exhibit 35. List of Cord Blood/ Stem Cell Banks in Australia	54
South Korean Stem Cells Market	55
South Korean Market Scenario	55
National Stem Cell Bank	55
CARTISTEM – World’s First Approved Stem Cell Drug for Degenerative Arthritis	55
President’s Promise to Fund Stem Cell Research	55
Hearticellgram-AMI	55
The South Korean Cord Blood Banking Sector	57
KRIBB	57
Chaum Life Center	58
Exhibit 36. List of Cord Blood/ Stem Cell Banks in South Korea	58
Exhibit 37. List of Major Asia-Pacific Stem Cells Companies	58
Analysis of Select Rest of Asia-Pacific Countries	59
Exhibit 38. Stem Cells – Rest of Asia-Pacific Market Estimations & Predictions (2005 - 2020) for Hong Kong, Taiwan, New Zealand, Malaysia and Singapore in US$ Million	59
Exhibit 39. Stem Cells – Rest of Asia-Pacific Market Shares (2010, 2015 & 2020) for Hong Kong, Taiwan, New Zealand, Malaysia and Singapore in US$ Million	60
Exhibit 40. List of Cord Blood/ Stem Cell Banks in Rest of Asia-Pacific	60
Hong Kong	61
Hong Kong Market Analysis	61
Exhibit 41. List of Cord Blood/ Stem Cell Banks in Hong Kong	61
Taiwan	61
Taiwanese Market Scenario	61
Exhibit 42. List of Cord Blood/ Stem Cell Banks in Taiwan	63
New Zealand	63
New Zealand Market Scenario	63
Exhibit 43.Cord Blood Bank in New Zealand	63
Malaysia	63
Malaysian Market Scenario	63
Singapore	63
Singaporean Market Scenario	64
Exhibit 44. List of Cord Blood/ Stem Cell Banks in Singapore	64
Rest of World Stem Cell Research Market	65
Exhibit 45. Stem Cells – Rest of World Market Estimations & Predictions (2005 - 2020) for Latin America, Middle East and South Africa in US$ Million	65
Exhibit 46.Stem Cells– Rest of World Global Market Shares (2010, 2015 & 2020) for Latin America, Middle East and South Africa	66
Exhibit 47. List of Major Companies in Rest of World	66
Latin American Stem Cells Market	67
Latin American Market Scenario	67
Exhibit 48. Stem Cells – Latin American Market Estimations & Predictions (2005 - 2020) for Brazil, Colombia, Mexico, Argentina and Rest of Latin America in US$ Million	68
Exhibit 49. Stem Cells – Latin American Market Shares (2010, 2015 & 2020) by for Brazil, Colombia, Mexico, Argentina and Rest of Latin America	69
Mexico	69
Mexican Market Scenario	69
Exhibit 50. List of Cord Blood/ Stem Cell Banks in Mexico	69
Brazil	70
Brazilian Market Scenario	70
Exhibit 51. List of Cord Blood/ Stem Cell Banks in Brazil	70
Colombia	70
Colombian Market Scenario	70
Exhibit 52.Cord Blood Bank in Colombia	70
Argentina	71
Argentinean Market Scenario	71
Exhibit 53. List of Cord Blood/ Stem Cell Banks in Argentina	71
Rest of Latin America	71
Rest of Latin America Market Analysis	71
Exhibit 54. Cord Blood/ Stem Cell Banks in Rest of Latin America	71
Middle East Stem Cells Market	72
Exhibit 55. Stem Cells – Middle East Market Estimations & Predictions (2005 - 2020) for Israel and Rest of Middle East in US$ Million	72
Exhibit 56. Stem Cells –Middle East Market Shares (2010, 2015 & 2020) by for Israel and Rest of Middle East	73
Israel	73
Israeli Market Scenario	73
Exhibit 57. List of Cord Blood/ Stem Cell Banks in Israel	74
Rest of Middle East	74
Rest of Middle East Market Analysis	74
Rest of Middle East Market Scenario	74
Exhibit 58. List of Cord Blood/ Stem Cell Banks in Rest of Middle East	75
African Stem Cells Market	75
South African Market Analysis	75
South African Market Scenario	75
Exhibit 59. List of Cord Blood/ Stem Cell Banks in South Africa	75
2. Stem Cells - Research market Trends	76
Stem Cell Therapy of Pets	76
Nobel Prize	76
In 2012, Prof. Shinya Yamanaka of Japan and Prof. John B. Gurdon of the United Kingdom shared the Nobel Prize for the discovery that mature cells can be reprogrammed to become pluripotent.	76
Setback for hESC Development	76
NIH Cannot Fund Embryonic Stem Cell Research, Judge Rules	76
New Method of Developing hESC Lines without Killing Human Embryos Discovered	77
Future of Cloned Food	78
Adult Stem Cells to Play Key Role in Heart Diseases	78
Use of Robotics in Stem Cell Research Automation	79
Identification of New Stem Cell with Dual Characteristics	80
Stem Cell Derivation from a Single Cell Extracted from Early Human Embryos	80
Reprogramming of Adult Stem Cells	81
Adult Stem Cells - Free of Controversy and Yield Better Results	81
Select Global Stem Cell Research Centers	82
3. Company Profiles - Major Companies in Stem Cells Market	90
Aastrom Biosciences, Inc. (USA)	90
Advanced Cell Technology, Inc. (USA)	91
apceth® GmbH & Co. KG (Germany)	93
ArunA Biomedical, Inc. (USA)	94
Asterias Biotherapeutics, Inc. (USA)	96
Athersys, Inc. (USA)	98
Axiogenesis AG (Germany)	99
Beike Biotechnology Co., Ltd. (China)	102
BioE, Inc. (USA)	104
Bioheart, Inc. (USA)	105
Bio-Master Co., Ltd. (Japan)	106
BioTime, Inc. (USA)	107
BrainStorm Cell Therapeutics, Inc. (USA)	109
Cardio3 BioSciences (Belgium)	110
Cell Care Pty. Ltd. (Australia)	111
Cellectis bioresearch (France)	111
Cellerant Therapeutics, Inc. (USA)	115
CellResearch Corporation Pte., Ltd. (Singapore)	116
Cells4Life Ltd. (UK)	116
Cellular Dynamics International, Inc. (USA)	117
Cesca Therapeutics, Inc. (USA)	119
CordLife Group Ltd. (Singapore)	121
Cryo-Cell International, Inc. (USA)	122
Cryo-Save South Africa (South Africa)	122
Cytomedix, Inc. (USA)	123
Cytori Therapeutics, Inc. (USA)	124
EMD Millipore (USA)	125
Epistem Holdings PLC (UK)	126
Equine Partners America LLC (USA)	129
Esperite NV (The Netherlands)	130
Fate Therapeutics, Inc. (USA)	130
Gamida Cell Ltd. (Israel)	133
GE Healthcare (UK)	135
Histostem Co., Ltd. (South Korea)	137
International Stem Cell Corporation (USA)	139
Life Technologies Corporation (USA)	141
LifebankUSA (USA)	143
LifeCell Corporation (USA)	143
MEDIPOST Co., Ltd. (South Korea)	143
Mesoblast Ltd. (Australia)	145
NeoStem, Inc. (USA)	146
Neuralstem, Inc. (USA)	148
NeuroGeneration, Inc. (USA)	149
Novartis AG (Switzerland)	150
Novo Nordisk A/S (Denmark)	151
Osiris Therapeutics, Inc. (USA)	151
Pluristem Therapeutics, Inc. (Israel)	153
Q Therapeutics, Inc. (USA)	154
ReInnervate Ltd. (UK)	156
Reliance Life Sciences (India)	156
ReNeuron Group PLC (UK)	159
RhinoCyte, Inc. (USA)	161
Roslin Cells Limited (UK)	161
SanBio, Inc. (USA)	162
Stem Cell Technology Research Center (Iran)	163
STEMCELL Technologies, Inc. (USA)	164
StemCells, Inc. (USA)	191
Stemedica Cell Technologies, Inc. (USA)	192
Stempeutics Research Pvt. Ltd. (India)	193
TiGenix NV (Belgium)	194
Trillium Therapeutics, Inc. (Canada)	195
ViaCord LLC (USA)	196
ViaCyte, Inc. (USA)	196
VistaGen Therapeutics, Inc. (USA)	199
Zellwerk GmbH (Germany)	200
4. Major Activities in Stem Cell Research Market	201
Reprocell Acquires Reinnervate	201
Sumitomo Dainippon Pharma Inks a Co-Development and License Agreement with SanBio for SB623	201
Cancer Research UK, CRT and Asterias Biotherapeutics Collaborates to undertake Clinical Trial of AST-VAC2 among Non-Small Cell Lung Cancer Patients	201
Vietnam based Hanoi Hematology Institute Unveils First Stem Cell Bank	202
NUI Galway and Mayo Collaborates on Joint Stem Cell Project	202
R&D Division of Esperite Incorporates GMP Stem Cell Bioproduction Technology	202
CORD:USE Inks An Exclusive Service Agreement with Tianhe	203
Gamida Cell Inks an Investment and Option Deal with Novartis	203
HLI Inks License Agreement with CCT	203
CCBC Alliances with Cordlife to offer Cord Blood Stem Cell Therapy Solutions to Patients in Asia	204
CWT Inks an Exclusive LOI with UC San Francisco	204
Aratana Gains Exclusive License for Commercializing Novel Regenerative Cell Therapy of Vet-Stem for Osteoarthritis Treatment	204
ScinoPharm Contracts with TaiGen for the Supply of Burixafor	205
Sangamo BioSciences Receives Strategic Partnership Award from CIRM for the clinical Studies of Stem-Cell Based ZFP Therapeutic® for HIV/AIDS	205
Roslin Cells and Pfizer Enter into New Cell Therapy Manufacturing Contract	206
NeoStem Acquires California Stem Cell Inc.	206
Bristol-Myers Squibb Acquires iPierian Inc.,	206
Cellular Dynamics International Ties-Up with AllCells	207
Vet-Stem Extends Licenses of Vet-Stem to Human Stem Cell Company	207
Bioheart Inks a Joint Venture Agreement with Magnum Cell Therapies	207
Catalent and Kyoto University Enter into Agreement for Regenerative Therapies	208
NeoStem Enters into Research Collaboration	208
FAMICORD Collaborates with CORDSAVINGS	208
Intrexon Acquires Medistem	209
Cytolon AG Global Cord Program Enters into Partnership with Mediware for Stem Cell, Cord Blood Bank Solution	209
Establishment of EBiSC	209
Vet-Stem and Petplan Collaborates to Offer Regenerative Cell Therapies for Pets	210
Establishment of Neurostemcellrepair	210
The Hamner Institutes and Cellular Dynamics Enter into Collaboration for the Development of In-Vitro Assays through utilization of Human iPS Cell-Derived Hepatocytes	210
Bioheart and StemMD Come Together	211
NYSCF Partners with personalgenomes.org to Merge Genomic Sequencing with Stem Cell Technology for Understanding of Human Disease	211
Vet-Stem Signs Partnership Agreement with Animal Health International for Regenerative Cell Therapies	211
ReachBio Inks an Exclusive Distribution Agreement with PeloBiotech	212
NYSCF Research Institute Alliances with Parkinson’s Progression Markers Initiative	212
Novartis Enters into a Worldwide Licensing and Research Collaboration Agreement with Regenerex for Application of FCRx Platform	213
Evotec in Association with Harvard Stem Cell Institute Forms CureMN Collaboration	213
Reinnervate Ltd., and Roslin Cellab Enter into Collaboration for 3D Stem Cell Printing Products and Technologies	213
ImStem Biotechnology Inaugrates cGMP Facility for Cell Therapy	214
Takara Bio to Globally Distribute Nippi’s iMatrix-511 Cells	214
ViaCyte Inc. Generates $ 10. 6 Million in a Private Sponsorship	214
Canada and Japan Come Together for Epigenetics of Stem Cell Research	215
Embryonic Stem Cell Research Unbanned in France	215
ThermoGenesis Unifies with Stem Cell Company	215
SynGen Permitted by US FDA to Market Stem Cell Therapy Products	216
International Market for Re-Load’s Nutraload Stem Cell Product Exceeds 3 Times the Initial Estimation	216
Americord Releases Sibling Cord Blood Reimbursement Policy	217
IndUS Pharmaceuticals Acquires Applied Protein Sciences	217
apceth Enters into Collaboration with Cytolon	217
apceth Receives Approval for first Ever Clinical Trial With Genetically Modified Adult Mesenchymal Stem Cells for Cancer Treatment	218
Stemedica Signs Worldwide Distribution Agreement with Life Technologies	219
Pall Collaborates with CMDG to Provide Innovative Cord Blood Processing Technology	219
Plasticell and Progenitor Labs Seed Cell Treatment Endeavours in Progress at the Stevenage Bioscience Catalyst Open Innovation University Grounds	220
VistaGen Therapeutics and Duke University Publish Outcomes on Production of Functional 3D Human Heart Tissue	220
EMD Millipore Commences OsteoMAX –XF – a Fully Defined Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium after Obtaining License from Plasticell	221
Vitro Biopharma and Neuromics Expands Collaboration to Target Drug Discovery and Regenerative Medicine Markets	222
Cell Cure Neurosciences Receives Financing from the Israeli OCS and a Bio Time Inc.	223
Coalition for the Advancement of Medical Research (CAMR) Transfers Mission and Assets to Alliance for Regenerative Medicine (ARM)	223
Stem Cell Therapeutics Corporation Issues Restricted Rights to Clinical Cancer Stem Cell Program	224
StemCells to Receive US$ 19. 3 Million from California Institute for Alzheimer’s Disease Treatment	224
Cellular Dynamics International Establishes Facility in California, to Deduce Bank Human Induced Pluripotent Stem Cells	225
VistaGen Therapeutics Enters into a Partnership with Celsis to Develop LiverSafe 3D	225
Cellectis and Stemgent Partner to Give Conventional Genome-Engineered iPS Cell	226
Histogen Establishes PUR Biologics, a Joint Venture to Develop Next-Generation Biologic Solutions in Orthopedic Applications	227
Mesoblast Decides to Raise $170million to Drive Advanced Programs To Commercial Outcomes by Collaborative Research	228
Medipost to Commence Cord Blood Cell Banking in Japan	228
STEMSOFT Teams Up with the Canadian Blood and Marrow Transplant Group	229
Stem Cell Therapeutics Unites with Reneu and Nexgen	229
National Institutes of Health Center for Regenerative Medicine Signs Contract with Lonza to Develop Research Grade iPSCs	230
SCT Signs a Merger Agreement with Trillium	230
Stem Cell Therapeutics Announces Joint-Venture Agreement	230
Medipost to Establish Corporate Body in Hong Kong	231
TiGenix Effectively Renews GMP License for its Stem Cell Manufacturing Facility in Madrid	231
Thermogenesis Decides to Sell Thermoline Product line to Helmer Scientific	231
Geron to Divest Stem Cell Assets	232
TiGenix Secures Renewal of GMP License for Stem Cell Manufacturing Facility in Madrid	232
SanBio Completes Enrollment of 2nd Dose Group of Patients for Clinical Trial of Stem Cell Therapy for Chronic Stroke	232
A New Company uses Regenerative Medicine to Corneal Transplantation	233
Verastem Enters Biomarker Agreement with LabCorp for Cancer Stem Cell Agent Companion Diagnostic	233
Cellular Dynamics and AstraZeneca Enter into Agreement to utilize iPSC-derived Human Cells in Drug Discovery Research	233
ReproCell Opens Office in Boston to Expand to US	234
GE Healthcare Life Sciences Starts A new £3 million Laboratories for Cell Science in Cardiff, Wales	234
Medipost Selected as the Largest Research Institute for Government Funding in the Field of Stem Cell Research	234
Roche and the Innovative Medicines Decides to Collaborate for Developing a Drug Based on Nobel Prize-winning Stem Cell Technology	235
The University College of London and Cellectis in Collaboration Agreement for Development of a T-cell Adoptive Immunotherapy to Treat Leukemia	235
Joint Study by Stemedica and Scripps Research Institute to Assess the Therapeutic Effect of Ischemia Tolerant Human Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis	236
Cytomedix Enters Collaboration to Study Pioneering Bright Cell Therapy for Peripheral Arterial Disease	236
OGI extends financial support to TRT for carrying out studies based on Stem Cell Technology	236
Pets Best Insurance covers Regenerative Stem Cell Therapy	237
MCW’s Stem Cell Therapeutics Outcomes Database Contract Renewal by Federal Government	237
International Stem Cell Corporation Announces Significant Progress towards Clinical Development	237
Umbilical Cord Cells are More Effective than Bone Marrow Cells	238
SCT enters into an Agreement with UHN and MaRS Innovation for a new, Clinical-Stage, Cancer Stem Cell Program	238
CHA Group Enters into a MOU with DISC Sports and Spine Center	239
Neural-like Stem Cells from Muscle Tissue may help in Carrying out Cell Therapy for Neurodegenerative Diseases	239
Cord Blood Registry Named Bioscience Company of the Year	240
Medistem Alliances with Superview Biotechnology on Development of Therapeutics Employing Antibody and Stem Cell Technology	240
Lonza and OncoMed Pharmaceuticals have signed a Process Development and Manufacturing Contract and Multi-product GS License Agreement for Anti-cancer Treatment	240
Vitrolife takes over Cryo Management Ltd	241
ThermoGenesis Signs Agreement With Golden Meditech Holdings Limited for its AXP® Product range for Purchase and Distribution	241
Lonza enters into License with iPS Academia Japan	241
Stemgent Acquires Human Tissue Business of Asterand	242
CeeTox and Cellular Dynamics Collaborate to Offer Predictive In-Vitro Test for Cardiotoxicity Utilizing Human iPSC-derived Cells	242
Plasticell and EMD Millipore Agrees to Distribute fully Defined, Xeno-Free Mesenchymal Stem Cell Differentiation Media	243
Pluristem and World-renowned Charité Berlin-Brandenburg Center for Regenerative Therapies Renew Five-Year Collaborative research Agreement	243
Pluristem Therapeutics Set to Enter Bone Marrow Disease market as it is Preparing to Apply for Orphan Drug Status with FDA for the treatment of Aplastic Bone Marrow	243
Celebrities Support the Initiative to Increase Organ and Stem Cell Donations	244
Scientists Reveal the effectiveness of Stem Cell Therapy in Treating Liver Cirrhosis	244
Medistem and Shanghai Jia Fu Medical Initiates a Clinical Trial on Critical Limb Ischemia patients	245
BGI, GE Healthcare Associate on Initiating Stem Cell Science Projects	245
CIC NanoGUNE and Inbiomed Merge Stem Cells and Nanotechnology	245
Plasticell Agrees to Provide Veritas an Exclusive Distribution Rights in Japan	246
MCW Inks a Partnership Agreement with Primorigen for Developing Novel Stem Cell Applications	246
Stemgent and iPS Academia Japan, Inc, Enter into Global Patent License Agreement	246
Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies	247
AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida	247
AlloSource Expands National Presence through New Partnership with Non-Profit Tissue Bank, LifeGift	247
KRIBB to Initiate Research Infrastructure for Xeno-Transplantation R&D	248
Fibrocell Science Inc Declares a License Contract with UCLA on Dermal Cell Research to further the Development of Personalized Cell Therapies	248
Fibrocell Science Technology helps to Discover Two Rare Adult Stem Cell like Subpopulations in Human Skin	248
Regulated development of Stem Cells	249
ReNeuron Enters into Cell Manufacturing Contract to Complete Stroke Clinical Trial. Recruitment of Patients for the Remaining Two Dose Cohorts on Track	249
Affymetrix and ScreenCell Enter Worldwide Distribution Agreement for Circulating Tumor Cell (CTC) Technology	249
$1-million to advance U-M Depression Center's Stem Cell research into bipolar disorder	250
WiCell Teams with Agilent Technologies to Offer High-Resolution CGH+SNP Microarray Service	250
AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Portuguese Company Crioestaminal	251
Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc. , Secures $20,000,000 in Institutional Funding	251
DaVinci Biosciences & Cellteam Biotechnology Combine Their Knowledge in the Stem Cell Field	251
VistaGen Therapeutics Enters into Agreement with Vala Sciences for Strategic Drug Screening	252
Cellular Dynamics Expands Distribution Agreement with iPS Academia Japan, Inc. to Include Distribution of iCell Neurons and iCell Endothelial Cells in Japan	252
Large-scale Stem Cell Cultivation Partnership Formalized	252
REMEDI to work with Chinese Universities	253
Stem Cells Inc. gives license to genOWay for gene insertion technology for genetically engineered mice	253
VistaGen Therapeutics Enhances its Drug Rescue Opportunities as a Result of an Agreement with Cato BioVentures and Cato Research	253
Baxter Completes Acquisition of Synovis	254
Lonza and Eclipse Therapeutics Entered into Developing and Production Contract	254
Stemina Awarded Third Phase I SBIR	254
Cytomedix Acquires Aldagen to Expand Regenerative Medicine Portfolio	255
Bioheart Acquires Exclusive Rights to Ageless Regenerative Institute’s Adipose Cell Technology	255
Pioneering Clinical Trials Study Cord Blood Stem Cells for Treatment of Brain Injury and Hearing Loss	255
Plasticell Agrees to Collaborate with Pfizer, Cellzome and University of Sheffield in a £1. 4 Million Technology Strategy Board-funded Stem Cell Project	256
Cellartis is Partner in InnovaLiv, a Major Multinational Regenerative Medicine Project Funded by the European Commission	256
UCSF and GE Healthcare team Decides to Collaborate inCord Blood Project	256
BioTime Licenses Technology for Vital Regulatory Gene Fundamental to Cancer and Stem Cell Reprogramming from the Wistar Institute	257
LoneStar Heart Acquires Exclusive Global Rights to New Class of Small Molecules with Potential for New Treatments for Diabetes	257
BioTime Enters into Agreement with USCN Life Science to Source Antibody-Based Products	257
PerkinElmer's ViaCord® Cord Blood Banking Business Collaborates with Miracle Babies to Improve Collection of Stem Cells from Premature Births for Potential Therapeutic Use	258
ThermoGenesis Signs Res-Q System Distribution Agreement with Arthrex	258
PerkinElmer Acquires Caliper Life Sciences	258
RNL Inaugurates Globally Largest Stem Cell Medical Center in Beijing, China	259
Medical Research Council Reconfirms Investment in Stem Cell Research	259
Cellectis Acquires Cellartis, to Focus on Personalized Medicine	259
Athersys and Fast Forward to Collaborate for the Development of MultiStem	260
NeoStem Acquires Amorcyte	260
UK-Israel to Establish Fellowship Exchange in Regenerative Medicine	261
California Stem Cell Acquires Cancer Stem Cell Therapy Program	261
Medistem Inc. Collaborates on Nanoparticle siRNA Finding in Therapy for Ischemic Conditions	261
Cassidy Medical Supply Teams Up with Provia Labs to offer Store-A-Tooth™ Dental Stem Cell Banking Facilities	261
Ysios-backed Cellerix and TiGenix Complete Merger	262
BioTime in Global License Agreement with Cornell University for Development and Commercialization of Vascular Cells Derived from Human Embryonic Stem Cells	262
Cedars-Sinai Establishes New Core Facility to Manufacture Induced Pluripotent Stem Cells	263
OncoCyte Corporation Expands Cancer Programs with US$10 Million Equity Financing	263
NeoStem Has Received Over US$1,700,000 in DOD Funding for its VSEL™ Technology Being Developed for Treating Osteoporosis	263
Plasticell Delivers Differentiation Protocols to Stemnion Inc.	264
ArunA Biomedical in Co-Marketing Agreement with HemoGenix	264
ReNeuron and Angel Biotechnology Enter New Manufacturing Agreement for ReN001	264
MultiCell Technologies, Inc. and University Health Network Work On the Evaluation of Two Potential Therapies for Liver Cancer Therapy	264
Arteriocyte and US Army Institute of Surgical Research (USAISR) Enter into CRADA to Accelerate the Cellular Therapies for Orthopaedic Trauma	265
ReNeuron Enters into Licensing Agreement with Schepens Eye Research Institute for Development of Stem Cell Therapies for Diseases of the Retina	265
Shire Completes Acquisition of Advanced BioHealing Inc.	266
Cord Blood America Buys NeoCells Inc’s Assets	266
Cryo-Cell Enters into Latin American Market	266
ATCC and iPS Academia Japan in Patent Licensing Agreement for Distribution of iPS Cells and iPS Cell-derived Cells	266
Cryo-Save and Lazaron Biotechnologies Establish Joint Venture on Stem Cell Bank in South Africa	267
iPS Academia Japan, Inc. to Distribute iCell® Products of Cellular Dynamics in Japan	267
Transposagen Inks Collaboration Agreement with SBI	267
NeoStem Signs Agreement with Nankai Hospital in Tianjin to Offer NeoStem's Licensed Orthopedic Technology	268
Cytori to Establish StemSource® Cell Bank for Neo Derm in Hong Kong	268
Takeda Ventures Strategically Invests in Fate Therapeutics	269
VistaGen Therapeutics and Excaliber Enterprises Announce Reverse Merger	269
ReNeuron Enters into Manufacturing Contract with NHS Blood and Transplant for Next-generation Stem Cell Product	269
Cellular Dynamics Licenses Technology from ViaCyte	270
US$ 6 Million Raised for New Cord Blood Bank in Australia	270
Plasticell Spins Out Regenerative Drug Discovery Venture	271
Sanofi-Aventis Completes Acquisition of Genzyme Corporation	271
International Stem Cell Corporation Receives Essential Approvals for Production of Parthenogenetic Stem Cell Lines in the United States	271
Yissum and Hadasit License Regenerative Polymeric Membrane Implants to RegeneCure	272
Beike Biotechnology to Upgrade Processing and Cryopreservation Technology to Expedite Advancements in Stem Cell Therapies	272
BioTime Acquires Glycosan to Merge with OrthoCyte	273
Indian and Californian Stem Cell Agencies Enter Agreement to Fund Collaborative Research Projects to Accelerate Regenerative Medicine towards Therapies	273
CIRM Enters into Stem Cell Research Agreement with ANR of France	274
Pluristem Therapeutics Teams up with NYU Medical Center for Examining PLX Cells Application in Treatment of Diabetic Foot Ulcers	274
Genzyme Completes Sale of Pharmaceuticals Business to International Chemical Investors Group	274
Stemline Licenses Brain Cancer Vaccine (Phase I and Phase 2 study)	275
CellSeed in Association with LA BioMed Plans to Launch Joint Research Project on Regenerative Medicine Technology	275
Cord Blood Collection Center Inaugurated in Leicester, UK	276
Genzyme Completes Sale of Diagnostic Products Business to Sekisui Chemical Co.	276
Kyoto University, iPS Academia Japan and iPierian in Global Licensing and Patent Assignment Agreement	276
Transposagen Inks a Non-Exclusive License Agreement with Cellular Dynamics International for Cross-Licensing Technologies for Induced Pluripotent Stem Cells	277
New Law Supports Advancement of Cord Blood Research	277
BioTime Acquires Assets of Cell Targeting, Inc.	278
BioCells Inc. , a Business of Cord Blood America, to Store Dental Pulp Stem Cells in Argentina	278
Essen BioScience Establishes Subsidiary in Japan	278
Transposagen Enters into License Partnership with Cellular Dynamics International	279
Embryome Sciences Adopts New Corporate Identity	279
NeoStem and Progenitor Cell Therapy Achieve Merger	280
Angel Biotechnology Holdings PLC in Contract with Pathfinder Cell Therapy	280
Kiadis Pharma Enters Licensing Agreement with Hospira for Commercialization of ATIR™ in Asia and Europe	280
KCI Obtains License to GRAFTJACKET® of Wright Medical for Wound Care	281
EHSI Employs NASA’s Intrifuge Rotary Cell Culture System in China	281
ARC Associates with Other Research Institutions for Reinforcing Special Research Initiative	281
InnovaStem Granted Manufacturing License to Separate Stem Cells from Cord Blood	282
BioTime Signs an MTA with the University of California System for Developing Five Human Embryonic Stem Cell Lines	282
BioTime Asia Inks a Marketing Agreement with SGMT for Supplying ACTCellerate™ Cell Lines in China and Other Areas	283
FamilyCord and Hoag Hospital Collaborate for Cord Blood Storage	283
Cord Blood America to Acquire Stem Cell Storage Company CryoCell Mexico	283
Mesoblast Acquires Angioblast	284
Mesoblast and Cephalon to Commercialize Novel Therapeutic Products for Regenerative Medicine	284
Korean Supreme Court Regards Stem Cells as Medicine	284
Plasticell and UCB in Small Molecule Drug Agreement	285
Plasticell and Sigma-Aldrich in Development Collaboration for Innovative Turnkey Solutions to Stem Cell Research	285
Cell Cure Neurosciences, Hadasit Bio Holdings, and Teva Pharmaceutical Industries Enter into an Exclusive License Agreement	286
FATE Enters into a Partnership Contract with BD	286
Medistem Collaborates with General Biotechnology LLC for Supplying ERC to Leading Universities and Leading Organizations	286
Stemedica International Partners with AnC Bio Group	287
Cellectis Gains Assessment for Induced Pluripotent Stem Cell Technology from iPS Academia Japan	287
CIRM Funds $72 Million Towards Translation of Basic Discoveries into New Therapies, Recruit Stem Cell Leaders to California	288
Medistem Join Hands with General Biotechnology LLC for Endometrial Regenerative Cells	288
Cryo-Cell Enters Industry-Exclusive Agreement with MedTech for Solutions, Inc. , A Group Purchasing Organization	289
Cord Blood America Enters into Agreement with the Hawaii Medical Service Association	289
Cord Blood America Completes Acquisition of BioCells	289
RTI Biologics and Athersys Enter Orthopedic Collaboration	289
Roslin Cells and Lonza in Development Collaboration for Pluripotent Stem Cell Media	290
First Indian Dual-Facility Cord Blood Bank Commences Operations	290
Stem Cell Facility Set up by Apollo Hospitals	290
Beike Biotechnology Establishes First Chinese Rehabilitation Center in Romania	291
Vitro Ties Up with Mokshagundam for Developing Cell Culture Medium	291
BioTime Establishes a New Subsidiary, OrthoCyte Corporation, for developing Stem Cell Technology based therapeutics for Orthopedic Disorders	292
STEMCELL Technologies Signs agreement with Stanford University	292
NIH Approves Advanced Cell Technology's Stem Cell Line for Federal Funding	293
Promega Enters into Partnership with Cellular Dynamics for the Validation of Stem Cell-Based In Vitro Assays	293
Thermogenesis Announces Divestiture of Cryoseal® Product Line	293
Shenzhen Beike Biotechnology and SiriCell Technologies Form Beike Holdings Limited, a Strategic Joint Venture for Stem Cell Therapies	294
Lifeforce Cryobanks Takes Over Cryobanks International’s Assets	294
Beike Biotechnology Expands Capacity	294
Cellular Dynamics Signs License Agreement with iPS Academia Japan	295
BioTime Acquires ES Cell International	295
Cytori Presents Study Report on Application of Stem & Regenerative Cells derived from Body Fat in Enhancing Heart Function in Chronic Ischemia Trial	295
Cryo-Save Enters into a Deal with Mutua Madrilena	296
Mesoblast Buys US based Angioblast Systems Inc.	296
International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing	297
genOway and Griffith University Enter into Research Partnership	297
International Stem Cell Corporation and the Automation Partnership Enter into Agreement to Automate Cornea Tissue Production	298
Thermogenesis Announces Global Res-Q Distribution Agreement with GE Healthcare	298
Novocell Adopts New Identity	298
Axiogenesis Secures Yamanaka Patent Portfolio	299
Fate Acquires Ontario based Verio Therapeutics to Boost Offerings in Stem Cell Modulator Range	299
ThermoGenesis Signs Asia Distribution Agreement with Fenwal for Bioarchive and AXP Systems	299
ReNeuron Signs Manufacturing Contracts with Angel Biotechnology	300
Axiogenesis Signs Worldwide Distribution Contract with Lonza Cologne	300
ThermoGenesis Announces Major Strategic Development with Completion of New Distribution Agreement with GE Healthcare	300
Stem Cell Therapy International and Histostem Merge to form AmStem International	300
First Cord Blood Processing and Cryopreservation Facility in Philippines Opened	301
Canadian Cord Blood Bank - Lifebank Achieves FACT Accreditation	301
China Cord Blood Corporation Acquires Stake in Shandong Cord Blood Bank	301
CORD:USE Cord Blood Bank and Memorial Healthcare System Enter Collaboration	302
Cord Blood America Signs Contract with BioE	302
ISCO Progresses Towards Establishment of the Industry’s First Universal Stem Cell Bank, UniStemCell™	302
BioTime Supplies Stem Cell Research Products to Millipore for Global Marketing of ACTCellerate™ Progenitor Cell Lines	302
Cryo-Save Successfully Completes Cord Blood Expansion Project	303
Athersys Signs Worldwide Agreement with Pfizer	303
Angel Biotechnology Receives Contract to Provide Regenerative Medicine Development Services	304
Celling Technologies Collaborates with Tissue Genesis for Prospective Incorporation of Adipose Tissue Stem Cell Technology in the area of Regenerative Medicine	304
Beike Biotechnology Invests Biomaster Inc.	304
Stem Cell Therapy International and Histostem of Korea Provide Hematopoietic Stem Cell to Queen Mary Hospital, Hong Kong	305
CordLife to Expand its Indian Network	305
STEMSOFT Software Inc. , Licenses StemLab® Software to Cord Blood America	305
Pfizer Takes Over Stem Cell Therapies Assets of Axordia	306
International Stem Cell Signs Collaboration Agreement with Scripps Research Institute’s Center	306
HSCI Co-operates with Novartis	306
VetCell is UK's First Official Equine Stem Cell Center	306
Cryo-Cell Licenses C`elle SM Technology to Cryopraxis Cryobiology	307
Gamida Cell Associates with Cellerix for Undertaking a Prospective Research	307
International Stem Cell and Absorption Systems Enter into Collaboration	308
Bioheart Makes Remarkable Medical Breakthrough with Stem Cells Obtained from Fat Tissue	308
California Stem Cell Enters into Collaboration with Stemina Biomarker Discovery	309
Bristol-Myers Squibb wholly Acquires Medarex	309
BrainStrom Signs Agreement with Harlan Biotech	309
Angel Enters Manufacturing Contract for Second-generation CTX Stem Cell Product with ReNeuron	309
Angel Biotechnology Enters into GMP Manufacturing Contract with Azellon Ltd. / University of Bristol	310
Novartis Takes Over Stem Cell Technology from Opexa	310
Expansion of Agreement between Cellular Dynamics International and Roche Pertaining to existing Cardiotoxicity Screening	310
LifeCell International Launches Cord Tissue Banking Service in Madurai	310
Neuralstem Deals with Taiwan based China Medical University for Developing Stem Cell Stroke Therapy	311
Takara Bio Inc. to supply RetroNectin® to U. S. and Europe for Multicenter Clinical Trials	311
GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies	311
MaRS and SLRI Co-Operate on Marketing of Umbilical Cord Stem Cell Technology for Potential Treatment in Various Diseases	312
REMEDI Introduces PurStem	312
Cellular Dynamics In-Licenses Key Patent Collection	313
Advanced Cell Technology Licenses Single Blastomere Technology to CHA Bio & Diostech Co. , Ltd. ,	313
ENKAM Pharmaceuticals A/S Enters into Partnership with STEMCELL Technologies	313
Cytori Collaborates with GE Healthcare for StemSource Products Marketing in the US	313
StemCells Inc. , Signs License Agreement with Key Pharmaceutical Company	314
Cellartis and ReproCELL Enter into Marketing Agreement to facilitate Cardiotoxicity Screening Service using hESC Derived Cardiomyocytes	314
StemCells Inc. , Takes Over Stem Cell Sciences plc	314
China Lays Foundation for Comprehensive Stem Cell Storage and Processing Facility	315
University of Utah’s Cell Therapy Lab Enters into Collaboration with Q Therapeutics for ALS	315
ISCO Enters into Agreement with Cytograft Tissue Engineering to Develop Therapeutic Medium for Cytograft’s Living Vascular Grafts	316
Epistem Enters into R&D Agreement with Novartis	316
ArunA Biomedical Enters into Distribution Agreement with Neuromics	316
ISSCR Excited for Future of Human Embryonic Stem Cell Research after Withdrawal of Funding Ban	316
AstraZeneca and Cellartis Extends Collaboration to Develop Innovative Drug Safety Testing	317
Cellartis Signs License Agreement for Commercialization of hES cell production With ITI life sciences	317
Parkwayhealth and Mesoblast to Provide Stem Cell Products	317
License Agreement between Cellartis and WARF for Human Embryonic Stem Cells	318
PerkinElmer and VRI™ Enter into an Agreement with M. D. Anderson Cancer Center for Extending the Research Collaboration	318
Intercytex Acquires Stem Cell Company Axordia Limited	318
ReNeuron Enters into License Agreement with Bio Focus DPI	319
VistaGen and Capsant Enter into Commercial Agreement for Stem Cell Technology	319
Novocell Enters into Collaboration with Shinya Yamanaka of Kyoto University	319
VistaGen and WARF Signs License Agreement for Human Embryonic Stem Cell Technology	320
VistaGen Receives Stem Cell Tools and Technologies Grant from California Institute for Regenerative Medicine	320
BioCell and Cellsense Merge	320
Joint Venture of Advanced Cell Technology and CHA Biotech named Stem Cell & Regenerative Medicine International	320
Cellular Dynamics International Amalgamates Sister Concerns	321
Cellular Dynamics International Receives Finance of US$500,000	321
Collaboration between Cellartis, Novo Nordisk and Lund University for development of insulin-producing cells from stem cells	321
ESI Join Hands with a major Pharma company for evaluation of GMP-Grade Stem Cell Lines	322
STEMCELL Technologies Launches AggreWell™ 400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research	322
International Stem Cell Corp. , and Novocell Enter into Collaboration for Treatment Solutions for Diabetes	323
GlaxoSmithKline Co-operates with Harvard Stem Cell Institute in the Area of Stem Cell Science	323
Angel Biotechnology and Angport in pre-GMP Development Program Contract	323
International Stem Cell Corp. , Enters into Agreement with Biotime and Embryome Sciences for Human Stem Cell Line Research	324
VivoMedica plc and Cellartis AB Enter into Collaboration for hESC Research	324
MedCell and NovaThera Merge for Musculoskeletal Regeneration	324
Angel Biotechnology and Novolytics in GMP Contract for Phase I/II clinical trials	325
ReNeuron Enters into Contract Agreement with Angel Biotechnology	325
WARF Grants License to Invitrogen for Research with Karyotypically Normal Human Embryonic Stem Cell	325
New Business Enterprise Formed to Develop Treatment with Adult and Cord Blood Stem Cells	326
KCI Acquires LifeCell for $1. 7 Billion in Cash	326
Osiris in Sale Agreement with NuVasive for Osteocel®	326
ImmuneRegen® Joins with BioCure for Developing New Wound-Healing Therapy	327
International Stem Cell Corporation Receives Exclusive Rights for Supplying Artificially Developed Human Skin Models	327
UCSD Joins consortium of Institutions for Research on Regenerative Technologies	328
Queensland gets a New Stem Cell Research Facility	328
Cordlife Ltd. Granted License to Establish New Cord Blood Stem Cells Bank in India	329
Asia-Cryo Cell Renamed as LifeCell International	329
Pentagon to Partially Finance a New Research on Regeneration of Limbs	329
CordLife Launches Largest Southeast Asian Cord Blood Bank in Singapore	330
MediHealth and NovaThera in Manufacturing and Marketing Agreement for NovaPod™	330
VistaGen Therapeutics in Stem Cell R&D Alliance with University Health Network of Toronto and the McEwen Center for Regenerative Medicine	330
Stem Cell Therapy International Plans Merger with Histostem	331
Cellartis and Pfizer in Research Collaboration for Development of Screening System to Detect Human Toxicity	331
Angioblast and Abbott in Heart Therapy Collaboration	331
Angel Biotechnology Enters into New GMP Manufacturing Contract	332
Osiris Therapeutics Reclaim Worldwide Rights to Prochymal™	332
BrainStorm and Rutgers University to Develop Spinal Cord Injury Therapy in Collaboration	332
StemCells, Inc. and Casey Eye Institute in Research Collaboration	332
Osiris Obtains $224. 7 Million Department of Defense Contract for Prochymal™	333
5. Major Product Innovations/Launches	334
GSK Receives FDA Approval for Additional Promacta® (eltrombopag) Application in Patients with SAA	334
Scientists Develop CellNet as Roadmap to Guide for Cell & Tissue Engineering	334
BioAdaptives Plans to Release PRIMICELL, the company’s First Product in the Market	335
Asterias Biotherapeutics Receives US FDA Approval to Initiate Phase 1/2a Trial of AST-OPC1	335
ViaCyte Attains ISO 13485:2003 Certification for the Proprietary Encaptra Drug Delivery System	336
Pevonia® Introduces new Stem Cells Phyto-Elite™	336
Beike Gains Approval from Chinese FDA for the Use of Human UC Derived MSCs for Systemic Lupus Erythamatosus (SLE) Treatment	336
Bioheart to Offer World’s First Combination Stem Cell Treatment	337
ViaCyte Submits IND Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate for Type 1 Diabetes treatment	337
Cord Blood America Introduces Mesenchymal Stem Cell Expanded Tissue Service	338
Bioheart Alliances with Dr. Walter Bell to Provide Cell Culture Expansion and Cryopreservation to the Citizens in South Africa	338
Dermarose® to Offer Two New Product Range including Swiss Rose Plant Stem Cells Through DermStore®	338
BrainStorm Receives Additional Patent for its Autologous Stem Cell Technology from USPTO	339
Cytori Receives Patent for Wound Healing Methods Utilizing Adipose-Derived Regenerative Cells	339
Medipost Obtains Technology Patent in Japan Utilizing Stem Cell to Treat Dementia	339
Fate Therapeutics Obtains US Patent for Class of Small Molecule Modulators Vital to develop iPSC-based Therapeutics	340
Roslin Cells to Produce Blood Cultured from Stem Cells	340
Bioheart to Initiate Clinical Study to Assess the Efficacy of AdipoCell™	340
Americord Introduces Corporate Giving Program	341
BrainStorm Enters into Definitive Agreement with MGH for ALS Clinical Trial	341
LifeMap Sciences Launches LifeMap Discovery® Version 1.6 with Tissue-Specific Fully Annotated Summaries of Gene Expression	341
BrainStorm Granted US Patent for its Key Autologous Stem Cell Technology	342
Verastem Gains Licenses of Cancer Stem Cell Inhibitor VS-4718	342
Verastem’s MTORC1/2 and PI3K VS-5584 Patented by JPO	343
WiCell Expands Offerings for Human Disease Research with Cell Lines of Life Technologies for Fluorescent Protein Expression	343
Irvine Scientific Launches New Cell Therapy Products for Cell Expansion and Differentiation	343
USPTO Issues Patent Covering Differentiation of iPS Cells into Endothelial, Hematopoietic Cells to Cellular Dynamics	344
Protide Pharmaceuticals Unveils New 2-8 CELLsius*Cold Storage Cell Solution	344
Cell Therapy Catapult & Roslin Cells to Create Clinical Grade Stem Cells to Accelerate Research for New Treatments	344
CORD:USE Ties-Up with Cedars-Sinai Medical Center	345
Macula Vision Research Foundation Grants US$300,000 to Neural Stem Cell Institute	345
Athersys Receives Small Business Innovative Research Program Fast Track Grant	345
Sceil: A Chance for People to Convert Adult Cells into Stem Cells and Store them	346
Phase III Study (MM-020/IFM 07-01) of Oral REVLIMID (Lenalidomide) in Recently Detected Multiple Myeloma Meets the Initial Conclusion	346
Stemedica Progress to Phase II Stroke Trial with Lead Product Stemedyne-MSC	347
Takara Bio Releases Nippi’s iMatrix-511 to Facilitate Growth of Human Stem Cells	347
US FDA Grants Orphan Drug Designation to Verastem’s Defactinib	347
Life Technologies Introduces Industry's First Stem Cell Characterization Panel	348
CSIRO Develops Test to Improve Stem Cell Safety	348
StemCells Spinal Cord Injury Trial Approved by Health Canada	349
Thermo Fisher Scientific Broadens Stem Cell Media Products - HyCell- STEM and HyCell-STEM-FF Systems	350
Phase 1 Clinical Trial of FAK Inhibitor VS-4718 in Patients with Advanced Cancer	350
Cellular Dynamics International Widens MyCell Product Line with Disease Models, and Genetic Engineering Patents	351
The European Commission Provides Orphan Medicinal Product Designation to Verastem’s VS-6063 in Mesothelioma	352
Life Technologies Launches a New Range of Stem Cell Reprogramming Solutions	352
BioTime and LifeMap Sciences Releases Improved LifeMap BioReagents Portal	353
LifeMap Sciences in Association with ProSpec-Tany TechnoGene Expands Product Line	354
MHRA Approves Expansion of Phase II Clinical Trial for MultiStem® Cell Therapy of Athersys in Ischemic Stroke	354
Harvard Apparatus Regenerative Technology's "InBreath" Scaffold and Bioreactor Used in First U.S. Transplant of a Regenerated Trachea	354
Regen BioPharma Files Investigational New Drug Application for HemaXellerate I for Aplastic Anemia	355
Health Canada Approves Kiadis Pharma’s Phase II Clinical Study with its Blood Cancer Treatment ATIR™	356
ATIR™	356
Medipost to Launch Stem Cell Culture Cosmetics	356
FDA Approves Mesoblast’s Use for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells in Singapore Manufacturing Facility	357
Kiadis Pharma Obtains U.S. Patent for its Blood Cancer Treatment ATIR™ Procedure	357
Cellular Dynamics Commences Production of Human iPSC Lines under cGMP Conditions	357
Biobest Announces the Launch of Quine Stem Cell Service marketed as Biobest Stem Cells	358
Thermo Fisher Scientific Adds Cryopreservation Reagents for Cell Culture Application	358
FDA Recommends Further Study for Gamida’s StemEx®	359
BioTime Isolates Seven Diverse Cartilage and Bone Cell Types from Human Embryonic Stem Cells	359
GE Healthcare and Cellular Dynamics International Accede to Sublicense for Cellular Assay Copyrights	360
US Patent to Axiogenesis for In-Vitro Drug Discovery Assay for Hypertrophic Cardiomyopathy	360
CIRM Grants more than $6 Million to UCLA Stem Cell Researchers	361
BioLife Solutions Announces TiGenix’s Completion of Stem Cells and HypoThermosol® Clinical Trial	361
UC Davis Dermatologist Receives Grant to Find New Method to Treat Chronic Skin Wounds	361
Stemedica Obtains US Patent for Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy	361
TiGenix Shuts Operations in Biomaterial Unit and Emphasizes on ChondroCelect and Proprietary Adipose Derived Stem Cell Products	362
Positive Results from Phase 1/2 POSEIDON Trial Demonstrate Donor (Allogeneic) Adult Mesenchymal Stem Cells (MSCs) Utilizing BioCardia Catheter Delivery Sy Stem Are Similarly Effective as Patients’ Own Stem Cells in Treating Ischemic Heart Failure	362
LifeMap Sciences, a Subsidiary of BioTime, Inc., Launches LifeMap Discovery™: A Database of Human Cellular Life for the Field of Regenerative Medicine	363
Cardio3 BioSciences to initiate the world’s first Phase III Clinical Trial in Regenerative Medicine for Heart Failure	363
Umbilical Cord Cells Demonstrates effective results than Bone Marrow Cells in Damaged Heart Repair	363
International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch	364
Newborn Human Foreskin Fibroblasts qualified for iPSC reprogramming launched by AMSBIO	364
VistaGen Therapeutics Launches LiverSafe 3D that helps in Predictive Liver Toxicology and Drug Metabolism Bioassay System	365
Stem Cells Being Used as Therapy for Diabetes	365
Axiogenesis Launches Cor.4U Human iPS Cell-Derived Cardiomyocytes	365
The National Institutes of Health Grants Contract Worth $6.9 Million for iPS Cells to Cellectis bioresearch Inc.	366
Sigma Life Science Launches Innovative, Affordable Pluripotent Stem Cell Culture Medium	366
Cellectis Stem Cells Launches Improved Format of Stem Cell Derived Cardiomyocytes	366
UC Davis Researcher Granted $1.3 million to Develop Bio-pacemaker from Stem Cells	366
CIRM Grants $37.3 Million to Assist UC Irvine Efforts	367
Store-A-Tooth™ Dental Stem Cell Banking Commits to "Find a Cure" for Type 1 Diabetes	367
Bio-Rad Launches TC20 Automated Cell Counter	367
Cellectis Stem Cells Launched New and Improved User Friendly Version of Stem Cell Derived Cardiomyocytes.	368
AllCells Launches Autoimmune Diseased Cells and Tissue Products	368
Swissmedic Grants Import/Export License to Stemedica for Stemedyne™ Stem Cell Line	369
Huntington's disease Research Fueled by $19 Million from CIRM	369
Advanced Bio Healing is Shire Regenerative Medicine Now	369
$14 million Grant to UC Davis for Stem Cell Research in Vascular Disease to Accelerate Therapy to Critical Limb Ischemia (CLI) Patients	370
Asahi Kasei Medical Co Decides to Buy Cryoseal® Product Line from ThermoGenesis	370
International Stem Cell Corporation Scientists Create New Protein-Based Stem Cell Technology	370
U-M Makes Six New Stem Cell Lines Available for Research	371
HemoGenix® FDA Master File to Measure Blood Stem Cell Potency for Cellular Therapy Products	371
HemoGenix® Launches the Largest Roll-Out of New Assays in its 11 Year History	371
ReproCell Launches Alzheimer’s Disease Model Based on iPS-derived Human Neuronal Cells	372
Prochymal, a Life-Saving Stem Cell Drug of Osiris, Granted Marketing Approval in New Zealand	372
Beike Receives AABB Accreditation for Storing Cord Blood and Cord Tissue	372
International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support is Therapeutic Programs	373
iPierian Advances Monoclonal Antibody Drug Development Programs Targeting Tau protein and the Complement Sy Stem for the treatment of Neurodegenerative Diseases.	373
Stemedica International and its Academic Partner Awarded Swiss Alzheimer’s and Stem Cell Research Grant	373
USC Stem Cell Research Lands $ 1.75 Million Grant	374
Cellectis Stem Cells Launches Globally First Human iPS Cell-derived Hepatocyte Product	374
VistaGen Obtains Important US Patent that Covers Stem Cell Technology Procedures that are Used to Test Drug Candidates for Liver Toxicity	374
Second U-M Stem Cell Line Made Available to Researchers to Find Treatment for Nerve Condition	375
VistaGen obtains license for advanced Stem Cell Culture Technology to Expedite development of Drug Screening and Cell Therapy for disorders of the Immune System	376
Roslin Cells to Manufacture iPS Cells for Bipolar Disorder Research	376
BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis Proposed Trial Will Build on NurOwn™ Platform to Meet Unmet Needs of Patients with Neurodegenerative Disorders	376
Researchers from Ottawa to Lead Globally-First Clinical Trial of Stem Cell Therapy for Septic Shock	377
BioVision, Inc. releases StemBoost™ "Ready-to-Use" cocktails for Stem Cell Research	377
U-M Human Embryonic Stem Cell Line Placed on National Registry	378
Nanotube Treatment Is now tried on Breast cancer Stem Cells	378
Baxter Initiates Phase III Adult Stem Cell Clinical Trial for Chronic Cardiac Condition	379
Stemedica Granted US Patent for Cellular Scaffold	379
Amorcyte, a Neo Stem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction	380
Faculty Members of University of Toronto Perform First Cardiac Stem Cell Transplant in Ontario	380
High Impact Research Projects at uOttawa Receive $1.9 Million Funding	381
BioTime to Manufacture Stem Cells for Research in Muscle Disorders	381
Cryo-Save India Awarded AABB Accreditation	381
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of the Proprietary Stem Cell Therapy in Type 2 Diabetes	382
Cellular Dynamics Commercially Launches iCell® Neurons for Neuroscience Drug Discovery	382
Cytori's Celution® One Sy Stem Awarded European CE Mark	382
First Stem Cell Bandage in Human Clinical Trials	382
FDA Approves First Cord Blood Transplant for Stem Cell Therapy	383
PerkinElmer’s Viacord® Cord Blood Banking Business to Expand Cell Harvesting Capabilities	383
Regulatory Clearance to Mesoblast for First Phase II Clinical Trial for Eye Diseases	384
Vitro Develops Stem Cell Technology for Hearing Impairment Treatment	384
Cytolon Commences Global Development of DIT - Distributed-Inventory-Technology™	385
StemCells, Inc Announces World’s First Neural Stem Cell Transplant in Patient with Spinal Cord Injury	385
ACT Receives Approval to Conduct First Human Embryonic Stem Cell Trial Analysis in Europe	385
VistaGen Therapeutics Receives Two Stem Cell Technology Patents	386
Cellular Dynamics Launches iCell® Endothelial Cells for Vascular-targeted Drug Discovery	387
ReN001 Stem Cell Therapy of ReNeuron Approved by DSMB for Higher Dose in Clinical Trial for Stroke	387
NIH Approves for Four GMP Human Embryonic Stem Cell Lines of BioTime	387
Stem Cell Therapeutics Obtains Patent for Vital Stem Cell Technologies with Expanded Geographic Coverage	388
Grant of Two Stem Cell Technology Patents Expands Patent Portfolio and Geographic Coverage of Stem Cell Therapeutics Corp.	388
Vitro Launches Latest Stem Cell Products	389
BioTime Issued Second U.S. Glycosan Hydrogel Patent	389
Data Monitoring Committee Approves Continuation of Phase III Clinical Study of StemEx®	390
Simple Method to Detect Breast Cancer at 'Stage 0' Discovered	390
International Stem Cell Corporation Begins Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells	391
International Stem Cell Corporation Innovates Method for Generation of Uncontaminated Liver Cells	391
Medi Stem Licensee RenovoCyte LLC Granted FDA INAD for Universal Donor Endometrial Regenerative Cells or ERC	392
TAP Biosystems to Launch New Automated Cell Culture and Maintenance Sy Stem for Stem Cell Research	392
Highly Effective Stem Cell Reprogramming Technology Has Been Introduced By Life Technologies Corporation	393
PerkinElmer’s ViaCord® Family Cord Blood Banking Business Announces First and Only Service to Bank Stem Cells Harvested from Umbilical Cord Tissue	393
Apollo Bramwell Hospital Launches Stem Cell Therapy Program	394
Cryo-Cell Launches New Service and Exclusive Family Healthcare Protection Plan	394
BrainStorm’s NurOwn™ Receives Ministry of Health Approval to Conduct First Clinical Trial Adult Stem Cell Therapy for ALS	395
TAP Biosystems’ CompacT SelecT™’s Innovative Options	395
Americord Registry Launches “Bank One, Give One” Cord Blood Program	396
Stempeutics Obtains Regulatory Approval to Conduct Clinical Trials in Malaysia	396
StemCells, Inc. Adds Serum-Free and Animal Component-Free Culture Supplements to its SC Proven(R) Product Portfolio	396
LifeCell Brings Menstrual Blood Stem Cell Banking to India	397
LifeCell International Launches Femme	397
StemCells Introduces Novel Purified Whole Cell Lysate Reagents to Proprietary SC Proven® Product pipeline	397
First Neural Stem Cell Study for Spinal Cord Injury Commenced	398
Vet-Stem’s Canadian Licensee Avivagen Delivers Stem Cell Therapy	398
HemoGenix® Launches LumiCYTE™-HT, a Contract Services In Vitro Hepatotoxicity Screening Platform	398
HemoGenix® Launches STEMpredict™	399
Life Technologies Receives FDA 510(K) Clearance for Stem Cell Growth Medium	399
Advanced Cell Technology Obtains Patent to Synthesize Embryonic Stem Cells without Embryo Destruction	399
NIH Re-evaluates and Approves Human Pluripotent Stem Cell Lines of Cellartis	400
Lonza and CSC Launches MotorPlate™ Human Esc-derived Motor Neuron Progenitors	400
UTHealth and Athersys Researchers Unveil the Preclinical Data Report Demonstrating Prospective Advantages of MultiStem® for Stroke Therapy	401
StemCord Receives Highest Cord Banking Accreditation	401
TAP Unveils CellBase CT™ for Advancing Ex-Vivo Expansion of Autologous Cell Therapies	401
Stempeucel from Stempeutics Cleared DCGI Application for Phase II Clinical Analysis	402
First HuCAL-based Antibody to Target Cancer Stem Cells in Clinical Trial	402
Aldagen Receives FDA Clearance for ALD-401	403
Advanced Cell Technology Obtained FDA Clearance to Treat Age-Related Macular Degeneration (AMD)	403
Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat	403
Stem Cell Therapeutics Corp. Receives Patent Associated with NTx® - 265	404
EHSI: Celulas Genetica Obtains Patent for their Ground Breaking Stem Cell Treatment	404
Arteriocyte Launches NANEX™	404
Medtronic Acquires Osteotech	405
International Stem Cell Launches Stem Cell based Range of Skin Care Products	405
AllCells Expands its Portfolio of Primary Adult Stem Cell Products	406
Geron Begins Clinical Trial of Human Embryonic Stem Cell-Based Therapy	406
SANYO Unveils an Exclusive Stand-Alone Cell Processing Work Station	407
Absorption Systems Obtains Patent for CellPort Technologies	408
BioCardia Declares Patent Issuance for Cardiac Regenerative Medicine using Stem Cell Therapy	408
Stemedica Completes Clinical Stem Cell Master Bank	409
Kansas-State University Receives Patent for Isolating, Culturing and Storing of Stem Cells	409
ReproCELL Launched Novel Services in Neuronal Research, Employing Human IPS Cells	409
FDA Approves Innovative Liver Cell Therapy for Clinical Trial in the US	410
Mesoblast Obtains TGA Regulatory Approval to Commercially Manufacture Adult Stem Products	410
AmStem Initiates US Study of Flagship Cosmeceutical Facial Cream Product SteMixx	410
TAP Launches Automated Stem Cell Processing Range	411
Advanced Cell Technology Receives Patent for Production of Retinal Pigment Epithelial Cells	411
United States Patents and Trademark Office Approves International Stem Cell Corporation’s Parthenogenetic Stem Cell Patent	411
New Cosmeceutical Beauty and Hair Restoration Products Launched by AmStem	412
FDA Grants Orphan Drug Designation to Osiris’ Stem Cell Treatment for Type 1 Diabetes	412
CCS Cell Culture Service GmbH Adopts the MaxCyte ® STX ™Scalable Transfection Sy Stem for Cell Line Development	412
Cryo-Save Introduces Novel Cryo-Lip® Stem Cell Storage Service	413
ViaCyte Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes	413
StemCells Inc. Plans to Advance Second Clinical Trial in Batten Disease	414
Millipore Markets Advanced Scepter™ Handheld Automated Cell Counter Globally	414
Thermogenesis Extends Global Reach for Bone Marrow Products with New Distribution Agreements	414
International Stem Cell Corporation Initiates Second Pre-Clinical Phase Testing of Retinal Pigment Epithelium (RPE)	415
Cord Blood Registry Introduces Industry-Leading Innovations for Newborn Stem Cell Collection	415
FamilyCord Launches Superior Cord Blood Collection Kit	415
Corning Unveils the Synthemax™ Surface for Application in Developing hESCs	416
Cellartis Launches Novel 2D Cardiomyocyte Product	416
CordLife Launches Advanced Human Stem Cell Technology in Hong Kong	416
StemCells, Inc. Granted Broad Patent for Pluripotent Rat Stem Cells and Genetically Engineered Rats	417
StemCells Introduces Cell Culture Medium	417
Fate Therapeutics Receives Patent for Induced Pluripotent Stem Cell Technology	417
USPTO Grants Patent to Athersys for Adult Stem Cell Composition & Production	418
Geron Undertakes Study for Analyzing the GRNOPC1 Effectiveness in Alzheimer's Disease Models	418
StemCells Launches First Cell Culture Medium	418
Cellular Dynamics Launches iCell™ Cardiomyocytes for Drug Candidate Toxicity Screening	419
Stem Cells Strengthens Patent Position in Embryonic and Induced Pluripotent Stem cell Technology Platforms	419
Embryonic and Induced Pluripotent Stem Cell Technology Platforms of StemCells Inc., further Reinforced	420
Mesoblast’s Trial Demonstrates Successful Results in Bone Marrow Regeneration in Cancer Patients employing Proprietary Stem Cells for Expanding Cord Blood	420
STEMCELL Technologies Launches Defined, Animal-Protein Free Maintenance Medium for hESCs and hiPSCs	421
STEMCELL Technologies Unveils MethoCult Express for Cord Blood Banks and Transplant Centers	421
Celling Technologies Introduces Novel Device for Strengthening Regenerative Medicine Range	421
International Stem Cell Corporation in Association with Reproductive Medicine Associates Announces Creation of New Source of Human Pluripotent Stem Cells	421
Lifeline Cell Technology Launches Innovative Products into the Human Cell Research Market	422
Technion-Israel Institute of Technology Develops Heart Cells from Human Skin Cells	422
Cytori’s Pilot Study Demonstrates Effective Treatment for SUI Using Adipose-derived Stem and Regenerative Cells	423
Mesoblast’s Proprietary Stem Cells Demonstrates Positive Preclinical trial Results in Degenerative Intervertebral Disc Disease Treatment	423
Neural Stem Receives FDA Approval for Human Trial for Treatment of Lou Gehrig's

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy